BioAdaptives Inc (BDPT)

[PENNYS ToMILLIONS]

2- THE MOVE FROM DEVELOPMENTAL STAGE company to one that’s Revenue Producing;

When analyzing a microcap’s chance at potential, it’s always easy to get lost in their UNFLATTERING Financials, derivatives and loans. It’s essential to the overall DD but equally important to put that debt feature in perspective. The key here is with products coming to market- and a brand new marketing and sales campaign in place for 2023 -$BDPT has moved to a different corporate stage.

What’s critical here is that PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. Their debts and obligations secured during the developmental stage have largely resulted in the current SS today and its necessity to maintain the 1.25bil AS. IMO- it was that satisfaction of debt that brought the cost down to a severely undervalued level.

FURTHER: for the OTC- 1.25Bil is still a very attractive AS and the OS currently listed around 420mil as of 5/31 - presents an opportunity for a continued accelerated rise from its current PPS.

If the financiers here (Kramer) allows this stock to breathe - heck - even puts a plug in any real overhang, this stock has a chance to accelerate to its proper market value which would result in a substantially higher PPS.